The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Phase:
PHASE2
Details
Lead Sponsor:
University of Southern California
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)